Dr. Reddy's Laboratories price target cut to $13.12, implying 1% downside
Average 12-month price target for Dr. Reddy's fell from $13.24 to $13.12 across 37 analysts. The consensus rating remains “Hold” across 39 covering analysts.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, citing FactSet data, the average 12-month price target for Dr. Reddy's Laboratories fell from $13.24 to $13.12. Forecasts from 37 analysts range from $10.85 to $16.57 per share.
Based on the October 23 closing price, the updated target implies a downside of roughly 1%. The consensus rating stays at “Hold”: of the 39 analysts covering the stock, 17 rate it Buy, 9 Hold and 13 Sell.
why it matters
The adjustment is small and shows that market expectations for the stock have barely changed. The consensus remains neutral, so the signal for India's pharmaceutical sector is more of a background indicator than a likely driver of prices.
tags
instruments
sources
- Dr. Reddy's Laboratories Ltd Stock 12‑Month Price Target Cut to $13.12, Implies 1% Downside — TradingView, 24 October 2026 at 04:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗